Marc Iskowitz

Marc Iskowitz

Marc Iskowitz has covered healthcare marketing, advertising and media for MM&M since 2005, but has followed the medical beat in a variety of roles since ‘96 or so. He has also moderated judging panels for the MM&M Awards. If you have story ideas, tips or criticism, e-mail me. And feel free to follow me on Twitter.

Most Recent Articles by Marc Iskowitz

Myelin acquires agencies in Chicago and Atlanta

Fourth and fifth members of network add healthcare advertising and PR expertise.

Pioneering info portal for doctors turns 20

Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.

Pharmanormal activities

Pharmanormal activities

When Monique Levy, one of the most-level-headed analysts in the pharma industry, calls attention to a mysterious phenomenon, you listen.

Makovsky's head of health moving to Finn Partners

Makovsky's head of health moving to Finn Partners

Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.

Editor's Desk: And the researchers go wild

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

More Articles by Marc Iskowitz

Disruption on display

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.